{"SPADE_UN_15547": {"Clinical Information": [], "Patent Information": [], "Sequence Information": {"SPADE ID": "SPADE_UN_15547", "Peptide Name": "HPRP-A1-iRGD", "Source": "Synthetic", "Family": "", "Gene": "Not found", "Sequence": "FKKLKKLFSKLWNWKCRGDKGPDC", "Sequence Length": 24, "UniProt Entry": ["http://www.uniprot.org/uniprot/Notavailable"], "Protein Existence": "Not found", "Biological Activity": ["Antimicrobial", "Anticancer"], "Target Organism": "Tumor cells:A549 (IC50=14.3 µM); MCF-7 (IC50=14.8 µM); NCI-H460 (IC50=15.2 µM); BGC-823 (IC50=18.5 µM); MDA-MB-231 (IC50=22.5 µM)", "Hemolytic Activity": "Human red blood cells:MHC=125 μM, MHC:the minimum hemolytic concentration is the concentration of peptide that results in 10% hemolysis of human red blood cells (hRBCs).", "Cytotoxicity": "HUVEC:IC50=26.5 μM", "Binding Target": "Not available", "Linear/Cyclic": "Linear", "N-terminal Modification": "Free", "C-terminal Modification": "Free", "Stereochemistry": "L", "Structure Description": "Not found", "Formula": "C136H213N37O31S2", "Mass": 2926.51, "PI": 9.93, "Net Charge": 6, "Hydrophobicity": -1.05, "Half Life": "Mammalian:1.1 hourYeast:3 minE.coli:2 min", "Literature": [{"Title": "Targeted Modification of the Cationic Anticancer Peptide HPRP-A1 with iRGD To Improve Specificity, Penetration, and Tumor-Tissue Accumulation", "Pubmed ID": "30592418", "Reference": "Mol Pharm. 2019 Feb 4;16(2)561-572.", "Author": "Hu C, Huang Y, Chen Y.", "URL": "http://www.ncbi.nlm.nih.gov/pubmed/?term=30592418"}], "Frequent Amino Acids": "KLC", "Absent Amino Acids": "AEHIMOQTUVY", "Basic Residues": 8, "Acidic Residues": 2, "Hydrophobic Residues": 8, "Polar Residues": 12, "Positive Residues": 8, "Negative Residues": 2, "Similar Sequences": [{"SPADE_ID": "SPADE_N_06400", "Similarity": 1.0, "Sequence": "FKKLKKLFSKLWNWK"}, {"SPADE_ID": "SPADE_UN_13041", "Similarity": 1.0, "Sequence": "FFKKLK"}, {"SPADE_ID": "SPADE_UN_15432", "Similarity": 1.0, "Sequence": "FKKLKKLFSKLWNWK"}]}}}